MRVI

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.